Share

Market insight in association with

Varian enters the embolisation particles market

Varian Medical Systems, which is based in Palo Alto, California, US, recently strengthened its interventional oncology business segment by acquiring two product lines from Boston Scientific and China-based Alicon in July 2019. Both transactions will result in the addition of embolisation particles to Varian’s product offerings. 


Embolisation particles can be used as an alternative to open surgery. The use of embolisation particles is minimally invasive and blocks blood flow to a particular area of the body. This can result in the shrinkage and ablation of an aneurysm or tumour. Four main types of embolisation particles are currently used in the market, including polyvinyl alcohol (PVA) particles, microspheres, drug-eluting beads, and radioembolisation particles. 


Embolisation particles are used to treat a variety of conditions including liver cancer, renal cell carcinoma, kidney cancer, neuroendocrine tumours, arteriovenous malformations, uterine fibroids, and benign prostatic hyperplasia. The increasing prevalence of cancer, hemorrhages, and malignant hypertension are key drivers of this growing market. 


Boston Scientific agreed to sell its Oncozene and Embozene microspheres for $90m. Oncozene microspheres are used for the embolisation of arteriovenous malformations (AVMs), hypervascular tumours (HVT) and hepatoma.


Embozene microspheres are used for the embolisation of prostatic arteries (PAE) for symptomatic benign prostatic hyperplasia (BPH). These assets generated over $20m for Boston Scientific in 2018. Varian does not expect this transaction to have financial implications for FY 2019. 


Alicon’s portfolio includes resorbable gel foam particles and PVA embolic beads. Alicon’s leading product is Caligel, which used in China to treat liver cancer. By acquiring Alicon, Varian will be able to use R&D programmes and networks that Alicon established in China. Varian spent $185m to purchase Alicon and the Texas-based company, Endocare. Together, these two companies had $30m in revenue, with 40% of this revenue coming from China. Similar to the purchase of the Oncozene and Embozene products, Varian does not expect the acquisition of Alicon to have financial implications in FY 2019. 


The global embolisation particles market is currently dominated by Boston Scientific and Merit Medical Systems. In 2019, Boston Scientific acquired BTG International, which manufactures microspheres, radioembolisation particles and drug-eluting beads. Therefore, despite the sale of its Oncozene and Embozene products, Boston Scientific is expected to continue to be a leader in the embolisation particle market.


In 2018, GlobalData estimated the global embolisation particles market to be worth over $1.03bn, with over $380m in revenue coming from the US. GlobalData predicts a compound annual growth rate of just over 5% for the US embolisation particles market over the next decade. If Varian continues to grow its embolisation business segment, it will be on its way to becoming a major player in this market. 

For more insight and data, visit the GlobalData Report Store.

Go to article: Home | Deep Space DiagnosticsGo to article: In this issueGo to article: MPS Microsystems Company InsightGo to article: MPS MicrosystemsGo to article: Contents Go to article: BioInteractions Company Insight Go to article: BioInteractions Go to article: Critical Software Company Insight Go to article: Critical SoftwareGo to article: NewsGo to article: Sandvik Company InsightGo to article: Sandvik Go to article: Omnitron Go to article: The Medical Industry Briefing Go to article: Sab BroeckskesGo to article: Formacoat Company InsightGo to article: FormacoatGo to article: Exceeding expectations: home sperm testing in the fertility tech marketGo to article: Siemens Company Insight Go to article: Siemens Go to article: Micro Systems TechnologiesGo to article: Space simulation: how gaming tech is being used to medically train astronautsGo to article: Braxton Manufacturing Go to article: CaelesteGo to article: Duodenoscopes: a dirty problemGo to article: Nelson Labs Company InsightGo to article: Nelson Labs Go to article: Mobile mind control: material engineering meets neurobiology Go to article: Abbott & CoGo to article: IMT Company InsightGo to article: IMTGo to article: Breathe easy: improving at-home asthma managementGo to article: Erdmann Design Company Insight Go to article: Erdmann Design Go to article: Q&A: the challenge of foetal monitoring with Professor Barrie Hayes-GillGo to article: Protomatic Medical Company InsightGo to article: Protomatic MedicalGo to article: Roundtable: debating the benefits of the NHS’s newly launched AI labGo to article: Europlasma Company Insight Go to article: EuroplasmaGo to article: The long road to reliable organ printingGo to article: SartoriusGo to article: Cap BiomaterialsGo to article: URGENT/11 vulnerabilities showcase cybersecurity risks for connected medical devicesGo to article: Telemed Company InsightGo to article: TelemedGo to article: Admedus turns focus to TAVR market with next-generation tissue technologyGo to article: Turck Duotec Company Insight Go to article: Turck DuotecGo to article: 3BYGo to article: Medtronic’s extravascular ICD is pushing innovationGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CRO Go to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Obstacle course for sperm is helping IVF scientists find the best swimmersGo to article: MicronovaGo to article: ARPA Company InsightGo to article: ARPAGo to article: Varian enters the embolisation particles marketGo to article: Ginolis Company InsightGo to article: GinolisGo to article: Verdict Insights: The latest verdict insight from Medical Technology Go to article: TEN MedPrint Company Insight Go to article: TEN MedPrint Go to article: Future of healthcare: What will medicine look like in 2040?Go to article: GF Machining Solutions Company InsightGo to article: GF Machining Solutions Go to article: 3D printing: Bringing assistive technology to the developing worldGo to article: iTAC Software Go to article: CarmoGo to article: Stepping up anatomical 3D printingGo to article: Key Plastics Company Insight Go to article: Key PlasticsGo to article:  Coaxial Electrospinning: Revolutionising MedicineGo to article: SARA: The robot targeting European elderly careGo to article: ClippardGo to article: Bright PlasticsGo to article: Asahi InteccGo to article: Bias in the system: the leading healthcare algorithm with bias against black patientsGo to article: Mdeg Digital Go to article: Maraca InternationalGo to article: OptelGo to article: Body cameras: The benefits in mental healthcareGo to article: CleanControlling MedicalGo to article: Abatek InternationalGo to article: XavitechGo to article: Take a seat: The mental health chatbots encroaching on the therapist’s couchGo to article: mdi ConsultantsGo to article: MK FluidicsGo to article: AI for sight: The technology transforming infant eye disorder diagnosisGo to article: ProByLas Go to article: ITV Denkendorf ProduktserviceGo to article: Deals in brief powered by GlobalDataGo to article: TS Quality & EngineeringGo to article: Mi3 Medical IntelligenceGo to article: The key list powered by GlobalDataGo to article: AerogelexGo to article: EventsGo to article: PI CeramicGo to article: Next issueGo to article: Qmedics Company Insight Go to article: QmedicsGo to article: Tresky